Beta Bionics, Inc.
BBNXHealthcareNASDAQMedical Devices · Last scanned Sep 7, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Beta Bionics, Inc. focuses on Medical Devices services and products. Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring. With a market capitalization of $873.7M, it sits in small-cap territory. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Market Cap
$873.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.39
EPS (TTM)
$-1.60
EPS (Fwd)
$-2.31
ROE
-26.2%
ROA
-16.7%
Cash
$180.5M
Total Debt
$6.5M
Free CF
-$40.3M
52W Change
-16.0%
Annual Financials
Cash vs Debt
Where BBNX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BBNX finished 43.14% above its 150-day moving average ($13.56) and 15.40% above its 200-day moving average ($16.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBNX overbought or oversold?
At the September 3, 2026 close, BBNX's RSI(14) was 59.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Beta Bionics, Inc. holds $180.5M in cash against $6.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$40.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $179K (2022) to $100.3M (2025), reflecting a 55906% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Beta Bionics, Inc.'s trajectory.